FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907623899> ?p ?o ?g. }

• W2907623899 endingPage "19997" @default.
• W2907623899 startingPage "19996" @default.
• W2907623899 abstract "The medical treatment of infectious diseases often requires combination therapies that blend two molecules to enhance drug efficacy. Nature does the same. In a new article, Mrak et al. identify and functionally characterize natural products from Streptomyces rapamycinicus that show synergistic antifungal activity with the well-known immunosuppressant metabolite rapamycin, produced by the same strain. The genomic co-association of the two biosynthetic gene clusters paves the way toward new strategies to discover synergistic pairs of antibiotics through large-scale genome mining. The medical treatment of infectious diseases often requires combination therapies that blend two molecules to enhance drug efficacy. Nature does the same. In a new article, Mrak et al. identify and functionally characterize natural products from Streptomyces rapamycinicus that show synergistic antifungal activity with the well-known immunosuppressant metabolite rapamycin, produced by the same strain. The genomic co-association of the two biosynthetic gene clusters paves the way toward new strategies to discover synergistic pairs of antibiotics through large-scale genome mining. Discovery of the actinoplanic acid pathway in Streptomyces rapamycinicus reveals a genetically conserved synergism with rapamycinJournal of Biological ChemistryVol. 293Issue 52PreviewActinobacteria possess a great wealth of pathways for production of bioactive compounds. Following advances in genome mining, dozens of natural product (NP) gene clusters are routinely found in each actinobacterial genome; however, the modus operandi of this large arsenal is poorly understood. During investigations of the secondary metabolome of Streptomyces rapamycinicus, the producer of rapamycin, we observed accumulation of two compounds never before reported from this organism. Structural elucidation revealed actinoplanic acid A and its demethyl analogue. Full-Text PDF Open Access Combination therapy is a promising solution for treating immunocompromised patients, resistant infections, and cancer. Particularly interesting are compounds that act synergistically—having efficacy greater than the sum of their individual contributions. Synergism can occur directly, by binding to the same target, or indirectly, by causing cascading effects in a targeted pathway. The utility of synergism is evident in several well-documented streptogramin antibiotics, such as Synercid. Considering the potency of such combinations, it is perhaps unsurprising that similar examples of synergistic compounds are found in nature. Several studies have identified the coordinated production of totally distinct compounds from adjacent biosynthetic gene clusters (BGCs) 2The abbreviations used are: BGCbiosynthetic gene clusterAPLactinoplanic acidPKSpolyketide synthaseNRPSnonribosomal peptide synthetase. that work together. The article by Mrak and colleagues (1Mrak P. Krastel P. Pivk Lukančič P. Tao J. Pistorius D. Moore C.M. Discovery of the actinoplanic acid pathway in Streptomyces rapamycinicus reveals a genetically conserved synergism with rapamycin.J. Biol. Chem. 2018; 293 (30327433): 19982-1999510.1074/jbc.RA118.005314Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar) adds a new example of such a “supercluster” for the production of rapamycin and the actinoplanic acids (APLs). This successful discovery of synergistic activity also outlines a potentially impactful strategy for prioritization of unknown BGCs, and thus possible combinatorial drug treatments, via synergistic cluster mining. biosynthetic gene cluster actinoplanic acid polyketide synthase nonribosomal peptide synthetase. The synergistic pairs found in nature thus far are quite diverse (Fig. 1). For example, Streptomyces rochei harbors a plasmid with two adjacent BGCs that encode the coordinated production of lankamycin and lankacidin, compounds shown to cooperatively attack the 50S ribosomal subunit (2Belousoff M.J. Shapira T. Bashan A. Zimmerman E. Rozenberg H. Arakawa K. Kinashi H. Yonath A. Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit.Proc. Natl. Acad. Sci. U.S.A. 2011; 108 (21282615): 2717-272210.1073/pnas.1019406108Crossref PubMed Scopus (51) Google Scholar). Likewise, the biosynthesis of members of several synergistic streptogramin antibiotic pairs, such as griseoviridin/viridogrisein, virginiamycin M and S, and pristinamycin I and II (3Mast Y. Weber T. Gölz M. Ort-Winklbauer R. Gondran A. Wohlleben W. Schinko E. Characterization of the ‘pristinamycin supercluster’ of Streptomyces pristinaespiralis.Microb. Biotechnol. 2011; 4 (21342465): 192-20610.1111/j.1751-7915.2010.00213.xCrossref PubMed Scopus (94) Google Scholar), is encoded in intertwined superclusters that produce each pair. Similarly, the BGC for the β-lactam antibiotic cephamycin C is co-localized with the gene cluster encoding the biosynthesis of clavulanic acid, an inhibitor of β-lactamases that could otherwise confer resistance to this antibiotic (4Ward J.M. Hodgson J.E. The biosynthetic genes for clavulanic acid and cephamycin production occur as a ‘super-cluster’ in three Streptomyces.FEMS Microbiol. Lett. 1993; 110 (8349096): 239-24210.1111/j.1574-6968.1993.tb06326.xCrossref PubMed Scopus (2) Google Scholar). Examples also occur outside actinomycetes: A supercluster in Bacillus encodes the biosynthesis of the synergistic lipopeptides fengycin and bacillomycin D (5Koumoutsi A. Chen X.-H. Henne A. Liesegang H. Hitzeroth G. Franke P. Vater J. Borriss R. Structural and functional characterization of gene clusters directing nonribosomal synthesis of bioactive cyclic lipopeptides in Bacillus amyloliquefaciens strain FZB42.J. Bacteriol. 2004; 186 (14762003): 1084-109610.1128/JB.186.4.1084-1096.2004Crossref PubMed Scopus (440) Google Scholar), one in Pseudomonas encodes the synergistic antibiotics mupirocin and jessenipeptin (6Arp J. Götze S. Mukherji R. Mattern D.J. García-Altares M. Klapper M. Brock D.A. Brakhage A.A. Strassmann J.E. Queller D.C. Bardl B. Willing K. Peschel G. Stallforth P. Synergistic activity of cosecreted natural products from amoebae-associated bacteria.Proc. Natl. Acad. Sci. U.S.A. 2018; 115 (29592954): 3758-376310.1073/pnas.1721790115Crossref PubMed Scopus (34) Google Scholar), and one in the fungus Aspergillus encodes the production of both fumagillin and pseurotin, although proof of synergistic action for this example is still pending (7Wiemann P. Guo C.-J. Palmer J.M. Sekonyela R. Wang C.C.C. Keller N.P. Prototype of an intertwined secondary-metabolite supercluster.Proc. Natl. Acad. Sci. U.S.A. 2013; 110 (24082142): 17065-1707010.1073/pnas.1313258110Crossref PubMed Scopus (133) Google Scholar). The work of Mrak et al. (1Mrak P. Krastel P. Pivk Lukančič P. Tao J. Pistorius D. Moore C.M. Discovery of the actinoplanic acid pathway in Streptomyces rapamycinicus reveals a genetically conserved synergism with rapamycin.J. Biol. Chem. 2018; 293 (30327433): 19982-1999510.1074/jbc.RA118.005314Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar) began by revisiting the compounds synthesized by the rapamycin producer Streptomyces rapamycinicus. The authors noticed two previously undetected compounds; isolation and structural elucidation indicated they were medically relevant APLs. Subsequently, genome re-sequencing and analysis led to the identification of a polyketide synthase (PKS) gene cluster with a domain architecture complementary to this structure. Experimental validation was carried out with in-frame deletions of several genes in the BGC, which revealed a single nonribosomal peptide synthetase (NRPS) module to be responsible for the incorporation of a rare tricarballylate moiety; comparison to the only other synthetic route to this moiety suggests an interesting case of convergent evolution. Further interrogation uncovered promiscuous domains and post-processing steps that resulted in a proposed complete biosynthetic pathway—the first for APLs. The APL gene cluster was also found consistently co-localized with the rapamycin BGC in the genomes of Streptomyces iranensis and Actinoplanes sp. MA7066, the only other genome-sequenced species that are known to make rapamycin. This suggested to the authors a possible synergistic relationship between the compounds. To test for possible effects, an antifungal assay was chosen based on the known activities of rapamycin and actinoplanic acids against the eukaryotic TOR complex and Ras farnesyltransferase, respectively. The results showed strong synergism against three fungal genera using concentrations within the production capacity of S. rapamycinicus. Clear results from Rhizopus oryzae showed growth inhibition at 1 nm rapamycin with 2 μm APL, in contrast to only slight inhibition at 25 nm and no activity alone, respectively. Given that the TOR complex is integral to basic cellular processes and farnesylated GTPases of the Ras family are often a part of the upstream signaling pathways, it was concluded that total arrest in growth is most likely achieved by APL-enhanced rapamycin activity. The authors noted that this example of co-associated products with synergistic potency highlights a new avenue that has yet to be exploited in genome-mining efforts. Computational analysis of microbial genomes has led to the identification of thousands of BGCs of unknown function, which beg for meaningful ways of prioritization to exploit them for drug discovery. Indeed, prioritizing predicted BGCs for the identification of synergistic product pairs is likely to yield useful antibiotics, as the synergy also poses a hurdle for resistance development. Although existing tools for identifying BGCs and grouping them into families across species (8Navarro-Munoz, J. C., Selem-Mójica, N., Mullowney, M. W., Kautsar, S. A., Tryon, J. H., Parkinson, E. I., de Los Santos, E. L. C., Yeong, M., Cruz-Morales, P., Abubucker, S., Roeters, A., Lokhorst, W., Fernandez-Guerra, A., Dias Cappelini, L. T., Thomson, R., et al. A computational framework for systematic exploration of biosynthetic diversity from large-scale genomic data. bioRxiv 10.1101/445270.Google Scholar) could be exploited to systematically identify BGC co-associations, it will be important to discriminate possible synergies from co-association “by chance,” e.g. due to recent common ancestry of closely related strains. Based on observations in known superclusters such as the rapamycin-APL case, we propose three criteria that could be leveraged. First, co-conservation across larger evolutionary time scales would distinguish real associations from associations due to recent common ancestry; this could be assessed through a statistical framework that takes into account the species phylogeny, and which offsets the degree of neutral sequence divergence and gene rearrangements against the level of co-association of pairs of BGCs within the same genomes (with a “bonus” for being located adjacently). Second, co-regulation of pairs of BGCs could be either predicted (through computational identification of transcription factor–binding sites) or assessed experimentally using transcriptome analysis. Third, the fact that synergistic molecules tackle the same target or related targets could be leveraged by employing approaches such as the antibiotic-resistant target seeker (ARTS) (9Alanjary M. Kronmiller B. Adamek M. Blin K. Weber T. Huson D. Philmus B. Ziemert N. The Antibiotic Resistant Target Seeker (ARTS), an exploration engine for antibiotic cluster prioritization and novel drug target discovery.Nucleic Acids Res. 2017; 45 (28472505): W42-W4810.1093/nar/gkx360Crossref PubMed Scopus (110) Google Scholar) pipeline to identify resistance genes co-associated with both BGCs. The latter would even make it possible to specifically pinpoint pairs that are likely to have novel mechanisms of action. Given the abundance of gene cluster families of unknown function that lie waiting in the riches of genomic data, this presents a promising new avenue for genome-based drug discovery." @default.
• W2907623899 created "2019-01-11" @default.
• W2907623899 creator A5027781296 @default.
• W2907623899 creator A5034845813 @default.
• W2907623899 date "2018-12-01" @default.
• W2907623899 modified "2023-10-10" @default.
• W2907623899 title "Mining bacterial genomes to reveal secret synergy" @default.
• W2907623899 cites W2020353075 @default.
• W2907623899 cites W2078001104 @default.
• W2907623899 cites W2113389111 @default.
• W2907623899 cites W2130014238 @default.
• W2907623899 cites W2131584678 @default.
• W2907623899 cites W2610680882 @default.
• W2907623899 cites W2794839960 @default.
• W2907623899 cites W2897713497 @default.
• W2907623899 doi "https://doi.org/10.1074/jbc.h118.006669" @default.
• W2907623899 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6311526" @default.
• W2907623899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30593529" @default.
• W2907623899 hasPublicationYear "2018" @default.
• W2907623899 type Work @default.
• W2907623899 sameAs 2907623899 @default.
• W2907623899 citedByCount "6" @default.
• W2907623899 countsByYear W29076238992021 @default.
• W2907623899 countsByYear W29076238992022 @default.
• W2907623899 countsByYear W29076238992023 @default.
• W2907623899 crossrefType "journal-article" @default.
• W2907623899 hasAuthorship W2907623899A5027781296 @default.
• W2907623899 hasAuthorship W2907623899A5034845813 @default.
• W2907623899 hasBestOaLocation W29076238991 @default.
• W2907623899 hasConcept C104317684 @default.
• W2907623899 hasConcept C141231307 @default.
• W2907623899 hasConcept C3742359 @default.
• W2907623899 hasConcept C41008148 @default.
• W2907623899 hasConcept C54355233 @default.
• W2907623899 hasConcept C70721500 @default.
• W2907623899 hasConcept C86803240 @default.
• W2907623899 hasConceptScore W2907623899C104317684 @default.
• W2907623899 hasConceptScore W2907623899C141231307 @default.
• W2907623899 hasConceptScore W2907623899C3742359 @default.
• W2907623899 hasConceptScore W2907623899C41008148 @default.
• W2907623899 hasConceptScore W2907623899C54355233 @default.
• W2907623899 hasConceptScore W2907623899C70721500 @default.
• W2907623899 hasConceptScore W2907623899C86803240 @default.
• W2907623899 hasFunder F4320321800 @default.
• W2907623899 hasIssue "52" @default.
• W2907623899 hasLocation W29076238991 @default.
• W2907623899 hasLocation W29076238992 @default.
• W2907623899 hasLocation W29076238993 @default.
• W2907623899 hasOpenAccess W2907623899 @default.
• W2907623899 hasPrimaryLocation W29076238991 @default.
• W2907623899 hasRelatedWork W2072064467 @default.
• W2907623899 hasRelatedWork W2093610003 @default.
• W2907623899 hasRelatedWork W2116326559 @default.
• W2907623899 hasRelatedWork W2146188580 @default.
• W2907623899 hasRelatedWork W2238553258 @default.
• W2907623899 hasRelatedWork W2340204314 @default.
• W2907623899 hasRelatedWork W2417312615 @default.
• W2907623899 hasRelatedWork W2944602870 @default.
• W2907623899 hasRelatedWork W2957309664 @default.
• W2907623899 hasRelatedWork W3005528502 @default.
• W2907623899 hasVolume "293" @default.
• W2907623899 isParatext "false" @default.
• W2907623899 isRetracted "false" @default.
• W2907623899 magId "2907623899" @default.
• W2907623899 workType "article" @default.